# Signals Article on Putative Target P05455 for Sjögren Syndrome
Background
The protein encoded by the putative target P05455 has emerged as a candidate of interest in the study of Sjögren syndrome, an autoimmune disorder characterized by the infiltration of lymphocytes into exocrine glands, leading to dry mouth and dry eyes. Preliminary findings suggest that P05455 may play a role in the inflammatory processes and immune dysregulation associated with Sjögren syndrome, indicating its potential as a therapeutic target. Given the complexity of this condition, further investigation into the molecular mechanisms involving this protein is essential for developing effective treatment strategies.Data-mining rationale
Our analysis utilized the GeoMicroarrayReanalysis approach, cross-referencing reviewed human entries in the UniProt database for "Sjögren syndrome" against 39 microarray datasets available in the NCBI Gene Expression Omnibus (GEO). The candidate UniProt:P05455 was identified as being present in several expression-profiling studies, yet it notably lacks any registered Phase 1 or higher clinical programs. This observation raises questions about its potential role in Sjögren syndrome and underscores the need for further exploration.Why prior analyses may have missed this
Many of the GEO datasets analyzed predate the implementation of modern empirical-Bayes statistical methods, such as the limma package, which provides robust multiple-testing correction. Consequently, previous analyses may not have accurately captured the expression dynamics of P05455 in the context of Sjögren syndrome. The absence of rigorous statistical validation could explain why this candidate has not been prioritized in the search for therapeutic targets in this autoimmune condition.Reasoning for further validation
To substantiate the potential role of P05455 in Sjögren syndrome, several experimental approaches are warranted: 1. Re-analyze the matched GEO datasets using the limma package with a Benjamini-Hochberg false discovery rate (FDR) threshold of < 0.05 to identify differentially expressed genes with greater confidence. 2. Validate the top differentially expressed genes, including P05455, by quantitative PCR (qPCR) in an independent cohort of Sjögren syndrome patients to confirm expression patterns. 3. Investigate the tissue specificity of P05455 expression using resources such as the Genotype-Tissue Expression (GTEx) project and the Human Protein Atlas to determine its relevance in exocrine and immune tissues. 4. Utilize pathway analysis tools like STRING and OmniPath to contextualize P05455 within known biological pathways related to inflammation and autoimmune responses in Sjögren syndrome. 5. If validation is achieved, assess the druggability of P05455 through databases such as DGIdb and ChEMBL to explore potential therapeutic interventions.References
- [UniProt: P05455](https://www.uniprot.org/uniprot/P05455)
- [UniProt: O43805](https://www.uniprot.org/uniprot/O43805)
- [UniProt: P10155](https://www.uniprot.org/uniprot/P10155)
- [UniProt: Q92805](https://www.uniprot.org/uniprot/Q92805)
- [UniProt: O60232](https://www.uniprot.org/uniprot/O60232)
- [NCBI GEO Accession GDS:200312709](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200312709)
- [NCBI GEO Accession GDS:200249144](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200249144)
- [NCBI GEO Accession GDS:200216815](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200216815)
- [NCBI GEO Accession GDS:200165515](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200165515)
- [NCBI GEO Accession GDS:200192985](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200192985)